Hastings C. David's most recent trade in Scynexis Inc was a trade of 23,000 Stock Option done . Disclosure was reported to the exchange on June 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 23,000 | 23,000 | - | - | Stock Option | |
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 23,000 | 69,183 (0%) | 0% | 0 | Common Stock | |
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 365,800 | 365,800 | - | - | Stock Option (Right to Buy) | |
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 90,100 | 249,824 (0%) | 0% | 0 | Common Shares | |
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.28 per share. | 04 Feb 2025 | 22,183 | 159,724 (0%) | 0% | 3.3 | 72,827 | Common Shares |
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 23,000 | 23,000 | - | - | Stock Option | |
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 23,000 | 46,183 (0%) | 0% | 0 | Common Stock | |
| Arbutus Biopharma Corp | C. Hastings David | Chief Financial Officer | 01 Feb 2024 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | ||
| Arbutus Biopharma Corp | Hastings C. David | Chief Financial Officer | 01 Feb 2024 | 112,500 | 191,500 (0%) | 0% | 0 | Common Shares | ||
| Arbutus Biopharma Corp | Hastings C. David | Chief Financial Officer | 01 Feb 2024 | 9,593 | 181,907 (0%) | 0% | 2.3 | 22,184 | Common Shares | |
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 10,000 | 23,183 (0%) | 0% | 0 | Common Stock | |
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option | |
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | 01 Feb 2023 | 316,000 | 316,000 | - | - | Stock Option (Right to Buy) | ||
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | 01 Feb 2023 | 79,000 | 79,000 (0%) | 0% | 0 | Common Shares | ||
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 10,000 | 13,183 (0%) | 0% | 0 | Common Stock | |
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | 20 Jan 2022 | 285,000 | 285,000 | - | - | Stock Option (Right to Buy) | ||
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | 13 Feb 2021 | 250,000 | 250,000 | - | - | Stock Options |